

July 31, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Outcome of the Board Meeting held on Friday, July 31, 2026

Dear Sir/Madam,

In furtherance to our intimation dated July 27, 2026, this is to inform you that pursuant to Regulations 30, 33, and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the Board of Directors of the Company at its Meeting held today, i.e., July 31, 2026, has inter-alia:-

- a) Considered and approved the Unaudited Financial Results (both standalone and consolidated basis) for the quarter ended on June 30, 2026 along with the Limited Review Report. A copy of the said Results is enclosed herewith as **Annexure – I**.
- b) Considered and approved the appointment of Mr. Harshad Purani as the Chief Financial officer and Key Managerial Personnel of the company with effect from July 31, 2026.
The details as required in terms of SEBI Listing Regulations and SEBI Master Circular dated January 31, 2026 are enclosed herewith as **Annexure – II**.
- c) Taken on record that Jupiter Hospital Pharmacy Private Limited (JHPPL), a subsidiary of the Company, has acquired 100% of the equity share capital of Sulcus Private Limited ("Sulcus") for a consideration of ₹3.78 crore. Consequently, Sulcus has become a wholly owned subsidiary of JHPPL and a step-down subsidiary of the Company. The details as required in terms of Listing Regulations and SEBI Master Circular dated January 31, 2026 are enclosed herewith as **Annexure – III and Annexure IV**.

The Board meeting commenced at 3:00 P.M. and was conclude at 3.45 P.M.

The aforementioned information will be available at the website of the Company at www.jupiterhospital.com.

You are requested to kindly take the afore mentioned on record and oblige.

Thanking you,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer
Encl : As stated above

KKC & Associates LLP
Chartered Accountants

(formerly Khimji Kunverji & Co LLP)
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai - 400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants

405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai - 400 080
Telephone: 65525689

Independent Auditor's Review Report on unaudited standalone financial results for the quarter ended 30 June 2026 of Jupiter Life Line Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Jupiter Life Line Hospitals Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results of Jupiter Life Line Hospitals Limited ('the Company') for the quarter ended 30 June 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the Statement for identification purpose only.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS, specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed



KKC & Associates LLP
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai - 400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants

405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai - 400 080
Telephone: 65525689

the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

5. Attention is drawn to the fact that the figures for the quarter ended 31 March 2026 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. The Standalone financial results include the financial information of 1 (one) partnership firm whose financial information being certified by the Management, reflects the Company's share of net loss after tax of Rs. 3.24 million for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this financial information are not material to the Company.
Our conclusion is not modified in respect of these matters.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621




Hasmukh B Dedhia
Partner
ICAI Membership No: 33494
UDIN: 26033494YEFSEK5657



Place: Mumbai
Date: 31 July 2026

For **Aswin P. Malde & Co.**
Chartered Accountants

Firm Registration Number: 100725W



Aswin P. Malde
Proprietor
ICAI Membership No: 032662
UDIN:



Place: Mumbai
Date: 31 July 2026

UDIN: 26032662TPJTQS8551

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 081

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ In Million)

Sl. No.	Particulars	Quarter Ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	(Refer Note 5)	Unaudited	Audited
1.	Income				
a.	Revenue from operations	3,284.85	3,124.23	2,779.87	11,976.24
b.	Other income	106.43	89.46	128.36	422.51
	Total Income	3,391.28	3,213.69	2,908.23	12,398.75
2.	Expenses				
a.	Purchases of medical consumables, drugs and surgical items	588.93	597.19	511.33	2,236.18
b.	Changes in inventories of medical consumables, drugs and surgical items	7.36	(42.13)	(3.69)	(103.40)
c.	Employee benefit expense	569.54	517.39	473.89	1,958.53
d.	Professional fees	804.06	725.94	644.08	2,864.99
e.	Finance costs	81.16	42.23	30.01	128.35
f.	Depreciation and amortisation expense	215.74	184.68	166.66	686.31
g.	Other expenses	623.36	544.50	478.45	2,018.54
	Total Expenses	2,890.15	2,569.80	2,300.73	9,789.50
3.	Profit before exceptional items and tax (1-2)	501.13	643.89	607.50	2,609.25
4.	Exceptional (loss)/ gain	-	11.55	-	(43.89)
5.	Profit before tax (3-4)	501.13	655.44	607.50	2,565.36
6.	Tax expenses				
a.	Current tax	124.89	98.11	179.16	621.44
b.	Short/ (Excess) Provision of earlier years	-	(7.42)	-	(7.42)
c.	Deferred tax charge/ (credit)	4.35	72.71	(4.60)	37.54
	Total tax expense	129.24	163.40	174.56	651.56
7.	Net Profit for the period/ year (5-6)	371.89	492.04	432.94	1,913.80
8.	Other Comprehensive income				
	Items that will not be reclassified to profit or loss				
(i)	Remeasurement of the defined benefit liabilities/ (assets)	-	2.57	-	2.57
(ii)	Deferred tax relating to items that will not be reclassified to Profit or Loss	-	(0.65)	-	(0.65)
	Total other comprehensive income/ (loss)	-	1.92	-	1.92
	Total comprehensive income for the period/ year	371.89	493.96	432.94	1,915.72
	Paid up Equity Share Capital (Face value ₹ 10 per share)	655.66	655.66	655.66	655.66
	Other Equity				15,419.91
	Earnings per equity share				
	Basic (in ₹)	5.67	7.51	6.60	29.19
	Diluted (in ₹)	5.67	7.51	6.60	29.19
		(Not annualised)	(Not annualised)	(Not annualised)	



AL

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 **Email:** info@jupiterhospital.com **Web:** www.jupiterhospital.com

NOTES TO THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

1. The unaudited standalone financial results of Jupiter Life Line Hospitals Limited ('the Company') for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2026. These results have been subjected to limited review by the joint statutory auditors of the Company, who have issued an unmodified report.
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India.
3. During the previous year ended March 31 2026, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. In accordance with the guidance issued by the Institute of Chartered Accountants of India and based on actuarial valuation, the Company has recognized Rs.43.89 million (net of subsequent reversal upon actualisation of charge) towards increase in the gratuity liability arising out of past service cost and enactment of the new legislation under "Exceptional Items" in the standalone financial results for the year ended March 31, 2026.
4. The Company is primarily engaged in the business of Healthcare services in India, which constitutes its only reportable business and geographical segment in accordance with Ind AS 108 - Operating Segments. Accordingly, no separate segment disclosures are required. Further, segment reporting for its Hotel division is not required, as its contribution to the Company's total revenue, profit, and assets is below the 10% thresholds specified under Ind AS 108.
5. The figures for quarter ended March 31, 2026 represent the difference between audited figures of the financial year March 31, 2026 and the unaudited published figures for the nine months ended December 31, 2025.
6. The proposed merger of Medulla Healthcare Private Limited ("Transferor Company"), a direct wholly-owned subsidiary of Jupiter Life Line Hospitals Limited ("Transferee Company") with the Transferee Company with effect from April 1, 2025 is pending final sanction of the Honourable National Company Law Tribunal, Mumbai. Thus, effect of the proposed scheme (being not material) is not given in the current financial statements of the Transferee Company.
7. Previous period figures have been regrouped and/or reclassified to conform to the current period presentation, wherever necessary.
8. The financial results are available on the Company's website (www.jupiterhospital.com) and on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

For Jupiter Life Line Hospitals Limited



Dr. Ankit Thakker

Dr. Ankit Thakker
Managing Director and CEO
DIN: 02874715

Place: Mumbai
Date: July 31, 2026



KKC & Associates LLP
Chartered Accountants

(formerly Khimji Kunverji & Co LLP)
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai - 400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants

405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai - 400 080
Telephone: 65525689

Independent Auditor's Review Report on unaudited consolidated financial results for the quarter ended 30 June 2026 of Jupiter Life Line Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Jupiter Life Line Hospitals Limited

Introduction

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Jupiter Life Line Hospitals Limited ('the Parent' or 'the Company') and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group') and its share of the net profit after tax and total comprehensive income for the quarter ended 30 June 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the Statement for identification purpose only.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ('the ICAI'). A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular Issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.



KKC & Associates LLP
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai - 400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants

405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai - 400 080
Telephone: 65525689

4. The Statement includes the result of the following entities:

Name of the entity	Relationship
Jupiter Life Line Hospitals Limited	The Parent
Jupiter Hospital Projects Private Limited('JHPPL')	Subsidiary
Medulla Healthcare Private Limited	Subsidiary
Jupiter Hospital Pharmacy Private Limited	Subsidiary
Katyayini Hospitality	Partnership Firm with Parent holding 95%

Conclusion

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

6. Attention is drawn to the fact that the figures for the quarter ended 31 March 2026 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Our conclusion on the Statement is not modified in respect of the above matter.

7. a) The Statement includes the financial results of 2 (two) subsidiaries, whose financial result reflects total revenues of Rs. 114.07 million, total net profit after tax of Rs. 19.70 million and total comprehensive income of Rs. 19.70 million for the quarter ended 30 June 2026, as considered in the Statement has been reviewed by Aswin P. Malde & Co., one of the joint auditors of the Parent, whose review report has been furnished to us by the Parent's Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the review reports of the other joint auditors, and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter with respect to our reliance on the work done and the review report of the other joint auditors.



KKC & Associates LLP
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai - 400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai - 400 080
Telephone: 65525689

b) The Statement include financial results of 1 (one) subsidiary whose Financial Results, reflect total revenue of Rs. 671.31 million, total net loss after tax of Rs.16.30 million and total comprehensive loss of Rs.16.30 million for the quarter ended 30 June 2026, as considered in the Statement. This financial results have been reviewed by other auditors and their reports, vide which they have issued an unmodified conclusion on those financial results, have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

8. The Statement also includes the financial information of 1 (one) partnership firm whose financial information being certified by the management, reflect the Group's share of net loss after tax of Rs. 3.41 million for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621




Hasmukh B Dedhia
Partner
ICAI Membership No: 33494
UDIN: 26033494LKARQC9479



Place: Mumbai
Date: 31 July 2026

For **Aswin P. Malde & Co.**
Chartered Accountants
Firm Registration Number: 100725W



Aswin P. Malde
Proprietor
ICAI Membership No: 032662
UDIN: 26032662CGLSEZ2074



Place: Mumbai
Date: 31 July 2026

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Sl. No.	Particulars	Quarter Ended			(₹ In Million)
		June 30, 2026	March 31, 2026	June 30, 2025	Year Ended
		Unaudited	(Refer Note 5)	Unaudited	March 31, 2026
1.	Income				Audited
a.	Revenue from operations	4,109.83	3,878.38	3,529.53	14,997.87
b.	Other income	105.86	91.49	128.17	423.68
	Total Income	4,215.69	3,969.87	3,657.70	15,421.55
2.	Expenses				
a.	Purchases of medical consumables, drugs and surgical items	796.74	768.49	710.60	2,991.43
b.	Changes in inventories of medical consumables, drugs and surgical items	3.88	(31.08)	(3.34)	(118.75)
c.	Employee benefit expense	744.52	677.17	617.15	2,563.25
d.	Professional fees	1,022.25	915.96	827.36	3,640.29
e.	Finance costs	128.62	90.08	82.70	326.63
f.	Depreciation and amortisation expenses	264.40	232.57	212.19	876.40
g.	Other expenses	749.75	656.21	593.56	2,489.07
	Total Expenses	3,710.16	3,309.40	3,040.22	12,768.32
3.	Profit before exceptional items and tax (1-2)	505.53	660.47	617.48	2,653.23
4.	Exceptional (loss)/ gain		15.09	-	(48.87)
5.	Profit before tax (3-4)	505.53	675.56	617.48	2,604.36
6.	Tax expenses				
a.	Current tax	131.75	103.94	184.44	644.91
b.	Short/ (Excess) Provision of earlier years	-	(7.48)	-	(7.42)
c.	Deferred tax charge/ (credit)	(1.34)	76.43	(6.41)	25.00
	Total tax expense	130.41	172.89	178.03	662.49
7.	Net Profit for the period / year (5-6)	375.12	502.67	439.45	1,941.87
8.	Other Comprehensive income				
	Items that will not be reclassified to profit or loss				
	(i) Remeasurement of the defined benefit liabilities/ (assets)	-	5.20	-	5.20
	(ii) Deferred tax relating to items that will not be reclassified to Profit or Loss	-	(1.18)	-	(1.18)
	Total other comprehensive income/ (loss)	-	4.02	-	4.02
	Total comprehensive income for the period/ year	375.12	506.69	439.45	1,945.89
	Profit/(Loss) attributable to:				
	i. Owners of the Company	374.86	506.15	438.86	1,944.08
	ii. Non-Controlling Interests	0.26	0.54	0.59	1.81
	Other Comprehensive income attributable to:				
	i. Owners of the Company	-	3.93	-	3.93
	ii. Non-Controlling Interests	-	0.09	-	0.09
	Total Comprehensive income attributable to:				
	i. Owners of the Company	374.86	506.06	438.86	1,943.99
	ii. Non-Controlling Interests	0.26	0.63	0.59	1.90
	Paid up Equity Share Capital (Face value ₹ 10 per share)	655.66	655.66	655.66	655.66
	Other Equity				14,785.18
	Earnings per equity share				
	Basic (in ₹)	5.72	7.66	6.69	29.59
	Diluted (in ₹)	5.72	7.66	6.69	29.59
		(Not annualised)	(Not annualised)	(Not annualised)	



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 **Email:** info@jupiterhospital.com **Web:** www.jupiterhospital.com

NOTES TO THE STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

1. The above consolidated financial results of Jupiter Life Line Hospitals Limited ('the Company') and its subsidiaries (together referred to as "the Group") for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 31, 2026. These results have been subjected to limited review by the joint statutory auditors of the Company, who have issued an unmodified report.
2. These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 - Interim Financial Reporting, as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015, the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India.
3. During the previous year ended March 31, 2026, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. In accordance with the guidance issued by the Institute of Chartered Accountants of India and based on actuarial valuation, the Company has recognized Rs.48.87 million (net of subsequent reversal upon actualisation of charge) towards increase in the gratuity liability arising out of past service cost and enactment of the new legislation under "Exceptional Items" in the standalone financial results for the year ended March 31, 2026.
4. The Group is primarily engaged in the business of Healthcare services in India, which constitutes its only reportable business and geographical segment in accordance with Ind AS 108 - Operating Segments. Accordingly, no separate segment disclosures are required. Further, segment reporting for its Hotel division is not required, as its contribution to the Group's total revenue, profit, and assets is below the 10% thresholds specified under Ind AS 108.
5. The figures for quarter ended March 31, 2026 represent the difference between audited figures of the financial year March 31, 2026 and the unaudited published figures for the nine months ended December 31, 2025.
6. The proposed merger of Medulla Healthcare Private Limited ("Transferor Company"), a direct wholly-owned subsidiary of Jupiter Life Line Hospitals Limited ("Transferee Company") with the Transferee Company with effect from April 1, 2025 is pending for final sanction of the Honourable National Company Law Tribunal, Mumbai. Thus, effect of the proposed scheme is not given in the current financial statements (being not material) of the Transferee Company.
7. In case of non-body corporates (partnership firms), consolidation is done considering these entities as subsidiaries and consequently the numbers for previous quarters, period and year are accordingly restated.
8. Previous period figures have been regrouped and/or reclassified to conform to the current year presentation, wherever necessary.
9. The consolidated financial results are available on the Company's website (www.jupiterhospital.com) and on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

For Jupiter Life Line Hospitals Limited



Dr. Ankit Thakker

Dr. Ankit Thakker
Managing Director and CEO
DIN: 02874715

Place: Mumbai
Date: July 31, 2026

Annexure II

Sr. No.	Particulars	Remark
1.	Name	Mr. Harshad Purani
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of CFO
3.	Date of appointment/ cessation / Change (as applicable) & Term of Appointment	Mr. Harshad Purani has been appointed as the Chief Financial Officer and Key Managerial Personnel of the Company w.e.f July 31, 2026.
4.	Brief Profile (in case of appointment);	Mr. Harshad Purani is the President – Administration and Head of Corporate Social Responsibility of our Company. He has been associated with our Company since September 9, 2007. He holds a bachelor's degree in commerce from the K. P. B. Hinduja College of Commerce and Economics, University of Bombay and an international executive masters of business administration degree from the United Business Institutes, Brussels. He is responsible for overseeing the overall administration and management of our Company across all locations. He has more than 20 years of experience.
5.	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not Applicable

Annexure- III

Sr. No.	Particulars	Remarks
1.	Name of the target entity, details in brief such as size, turnover, etc.;	Sulcus Private Limited Size & turnover: NIL
2.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, the nature of interest and details thereof and whether the same is done at “arm’s length”;	Yes. The acquisition constitutes a related party transaction as Jupiter Hospital Pharmacy Private Limited, a subsidiary of the Company, has acquired the equity shares of Sulcus Private Limited from Dr. Ankit Thakker and Mrs. Kirtika Thakker, who are members of the Promoter and Promoter Group of the Company and are related parties of the Company. Prior to the acquisition, Dr. Ankit Thakker and Mrs. Kirtika Thakker collectively held 100% of the paid-up equity share capital of Sulcus Private Limited. The acquisition has been undertaken on an arm's length basis pursuant to an independent valuation.
3.	Industry to which the entity being acquired belongs;	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	JHPPL is in the business of running and operating retail pharmacy stores in all Jupiter Hospitals and elsewhere. With growing footprint of Jupiter Hospitals, the scale of operations of JHPPL is also going to increase. In order to reduce costs and improve margins, JHPPL has acquired the entire shareholding of Sulcus Private Limited, which has an industrial land near Ujjain, Madhya Pradesh, on which it is in the process of setting up an IV fluids, infusions and pharmaceutical manufacturing facility.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	DMIC Vikram Udyogpuri Limited has granted prior permission vide no. DMIC/VUL/LM/2026/121 dated 30/06/2026.
6.	Indicative time period for completion of the acquisition;	SPA signed today i.e. 31/07/2026
7.	consideration - whether cash consideration or share swap or any other form and details of the same;	Cash Consideration
8.	Cost of Acquisition or the price at which the shares are acquired;	The total cost of acquisition Rs. 3.78/- Crores determined based on an independent valuation report.
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	100% of the paid-up equity share capital comprising 10,000 equity shares.

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<u>Brief background about the entity acquired:</u> Sulcus Private Limited is a company incorporated under the Companies Act, 1956 and is engaged in the process of setting up an IV fluids, infusions and pharmaceutical manufacturing facility near Ujjain, Madhya Pradesh. <u>Date of Incorporation:</u> 23/08/2012 <u>History of last 3 years of Total Turnover</u> NIL, in the process of setting up manufacturing unit. <u>Country in which the acquired entity has presence:</u> India
-----	---	--

Annexure IV

Sr. No.	Particulars	Remarks
1.	Industry or area to which the new line of business belongs to;	Pharmaceuticals
2.	Expected benefits;	JHPPL is in the business of running and operating retail pharmacy stores in all Jupiter Hospitals and elsewhere. With growing footprint of Jupiter Hospitals, the scale of operations of JHPPL is also going to increase. In order to reduce costs and improve margins, JHPPL has acquired the entire shareholding of Sulcus Private Limited, which has an industrial land near Ujjain, Madhya Pradesh, on which it is in the process of setting up an IV fluids, infusions and pharmaceutical manufacturing facility.
3.	Estimated amount to be invested.	Rs. 35-40 crores for one line of blow-fill-seal IV fluid filling machine over 1-2 years.